Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today is pleased to announce the first patient has been enrolled and treated in the Company’s Phase I/II clinical trial investigating the use of NTI164 in female Rett Syndrome patients. Dr Thomas Duthy, Executive Director of Neurotech International said “On behalf of Neurotech we warmly congratulate our Principal Investigator Associate Professor Carolyn Ellaway, on commencing this important trial in Rett Syndrome which seeks to provide initial evidence on the safety and efficacy of NTI164 in this patient population. Following on from our successful presentation at the 2023 International Rett Syndrome Scientific Meeting in Tennessee, there is a need for safer and more effective therapies that target the persistent neuroinflammation associated with this rare neurological disorder. Recent corporate activity in the Rett Syndrome therapeutic space highlights to us the significant opportunity ahead for the Company in developing NTI164 for this patient population.”
